240 related articles for article (PubMed ID: 27752357)
1. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.
Strand V; Lee EB; Fleischmann R; Alten RE; Koncz T; Zwillich SH; Gruben D; Wilkinson B; Krishnaswami S; Wallenstein G
RMD Open; 2016; 2(2):e000308. PubMed ID: 27752357
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Strand V; Burmester GR; Zerbini CA; Mebus CA; Zwillich SH; Gruben D; Wallenstein GV
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):475-83. PubMed ID: 25186034
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
5. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
[TBL] [Abstract][Full Text] [Related]
6. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
[TBL] [Abstract][Full Text] [Related]
7. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
12. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
[TBL] [Abstract][Full Text] [Related]
13. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G
RMD Open; 2017; 3(2):e000496. PubMed ID: 28955499
[TBL] [Abstract][Full Text] [Related]
14. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis.
Fleischmann R; Strand V; Wilkinson B; Kwok K; Bananis E
RMD Open; 2016; 2(1):e000232. PubMed ID: 27175296
[TBL] [Abstract][Full Text] [Related]
15. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
[TBL] [Abstract][Full Text] [Related]
16. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Strand V; van der Heijde D; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Clin Exp Rheumatol; 2020; 38(5):848-857. PubMed ID: 31858963
[TBL] [Abstract][Full Text] [Related]
19. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
